Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
== Definition == The term "niacin" was originally coined from "nicotinic acid vitamin", with the goal of distancing the nutrient B3 from the drug nicotine in tobacco. As a result, it originally referred to the nutritional entity of vitamin B3. However, in American English, the term has also come to mean "nicotinic acid" in the context of high-dose use as a prescription medicine. In other varieties of English, the medicine is only ever called "nicotinic acid". The term "nicotinic acid" unambiguously refers to the substance and the prescription medicine containing it, which treats elevated cholesterol and triglycerides. When used as a drug, daily doses range from 500 to 3,000 mg/day. High-dose nicotinamide does not have this medicinal effect.
== Fame == Vanity Fair name her one of the "50 French Women who made 2020", alongside Adèle Haenel and Virginie Despentes. Technikart named her as one of the "100 who can save 2021". Website Brut named her on a panel of "31 who made 2022 happen". Étienne gained wider media attention in early 2023, when she allegedly had an affair with dancer and choreographer Benjamin Millepied, who was married to actress Natalie Portman at the time. On March 8, 2024, it was announced that Portman and Millepied had divorced.
Additionally, they were able to tune the retention factor for the analytes through isocratic temperature gradient elution. Ideal elutions occurred at 35 °C, but decreasing the temperature to 10 °C or raising it to 50 °C caused faster elutions either way. This is a strong indication that electrostatic and hydrophobic interactions can be similarly affected by changes in temperature. The major advantages from applying these success of this study include stationary phase versatility and maintaining bioactivity of the analytes. Ayano et al. modified PNIPAAm with cationic N,N-dimethylaminopropylacrylamide (DMAPAAm) and hydrophobic BMA and grafted it onto silica beads to form IDB. They used pH changes to adjust the LCST. The effect of pH on the LCST is as follows, from a plateau value between pH 4.5 and pH 6.0, the LCST decreased up to pH 9 and below pH 4.5. This can be interpreted as requiring slightly basic or moderately acidic conditions, as the 4.5–6.0 pH region holds a maximum value of the LCST, an unfavorable condition. They used these properties to separate several non-steroidal anti-inflammatory drugs (NSAIDs). The analysis of acidic drugs (salicylic acid: BA; SA; MS; and As) was performed below pH 4.5. MS is hydrophobic only its retention time was affected by an increase in temperature on the column without a terminally modified anion-exchanger (IB column). However, with an anion-exchanger present, dissociated acidic drugs were retained longer at temperatures below LCST, and shorter at temperatures above LCST.
Sources: en.wikipedia.org
In early May 1990, one of the two A&M researchers, Kevin Wolf, acknowledged the possibility of spiking, but said that the most likely explanation was tritium contamination in the palladium electrodes or simply contamination due to sloppy work. In June 1990 an article in Science by science writer Gary Taubes destroyed the public credibility of the A&M tritium results when it accused its group leader John Bockris and one of his graduate students of spiking the cells with tritium. In October 1990 Wolf finally said that the results were explained by tritium contamination in the rods. An A&M cold fusion review panel found that the tritium evidence was not convincing and that, while they couldn't rule out spiking, contamination and measurements problems were more likely explanations, and Bockris never got support from his faculty to resume his research. On 30 June 1991, the National Cold Fusion Institute closed after it ran out of funds; it found no excess heat, and its reports of tritium production were met with indifference. On 1 January 1991, Pons left the University of Utah and went to Europe. In 1992, Pons and Fleischmann resumed research with Toyota's IMRA lab in France. Fleischmann left for England in 1995, and the contract with Pons was not renewed in 1998 after spending $40 million with no tangible results. The IMRA laboratory stopped cold fusion research in 1998 after spending £12 million. Pons has made no public declarations since, and only Fleischmann continued giving talks and publishing papers.
=== Development === In March 2015, Rajinikanth was reported to have signed his next film with AR Murugadoss and producer V. Ravichandran of Aascar Films; the project was reported to have been out on hold until his issue with the distributors over the financial losses of his film Lingaa (2014) was resolved. The project was never realised due to Ravichandran's bankruptcy. On 25 September 2018, media reported Rajinikanth would collaborate with Murugadoss for his next project and would be financed by Sun Pictures, which produced the latter's Sarkar (2018) and the former's Petta (2019). On 25 November that year, Lyca Productions announced it would collaborate with Rajinikanth and Murugadoss again after their previous collaboration of the former's 2.0 (2018) and the latter's Kaththi (2014) . At an awards ceremony held in December 2018, Murugadoss stated the film was not about politics like some of his previous films but a "mass entertainer". Production of the film began with the working title Thalaivar 167. Composer Anirudh Ravichander and cinematographer Santosh Sivan confirmed their involvement in the film. On 9 April 2019, Lyca Productions released the film's first-look poster on social media platforms, revealing the film's title as Darbar. The first look of Rajinikanth had him surrounded by police dogs, belts, badges and handcuffs. It was Rajinikanth's first role as a police officer after 27 years, his previous police role being in Pandiyan (1992).
== More studies and projects == Brain Age: Environmental influences in prenatal life have a major impact on brain aging and age-associated brain disorders. Aging is considered as a major risk factor of most neurogenerative diseases such as Alzheimer's or Parkinson's disease for example. EuroBATS: Studies that uses both genetic and biological approaches. Study of 8,000 identical twins to identify markers of aging. The use of improving the length of the telomeres will be used in this process. Frailomic: Utility of biomarkers to characterize elderly individuals at risk for frailty, its progression to disability outcomes, and overall health and well-being consequences. The main objective is to prevent and detect frailty before suffering from it.
== Production == Bulk carbon-13 for commercial use, e.g. in chemical synthesis, is enriched from its natural 1.1% abundance. Carbon-13 can be separated from the major carbon-12 isotope via techniques such as thermal diffusion, chemical exchange, gas diffusion, laser, cryogenic distillation, or chemical exchange of CO2 , however, only cryogenic distillation of methane (boiling point −161.5 °C) or carbon monoxide (b.p. −191.5 °C) is economically feasible for industrial production as of 2010. Industrial carbon-13 production plants represent a substantial investment: greater than 100-meter-tall (330 ft) cryogenic distillation columns are needed to separate the carbon-12 or carbon-13 containing compounds. The largest reported commercial carbon-13 production plant in the world as of 2014 has an annual production capability of ~400 kg of carbon-13. In contrast, a 1969 carbon monoxide cryogenic distillation pilot plant at Los Alamos Scientific Laboratories could produce 4 kg of carbon-13 annually.
Sources: en.wikipedia.org
== External links == P. Romano, C. Fiore, M. Paraggio, M. Caruso, A. Capece "Function of yeast species and strains in wine flavour". Archived 2015-06-06 at the Wayback Machine. International Journal of Food Microbiology 86 (2003). pp. 169–180.
== Other deposits == In Poland diatomaceous earth deposits are found in Jawornik, and are composed mostly of diatomaceous skeletons (frustules). In Germany, diatomaceous earth was also extracted at Altenschlirf on the Vogelsberg (Upper Hesse) and at Klieken (Saxony-Anhalt). There is a layer of diatomaceous earth more than 6 meters (20 ft) thick in the nature reserve of Soos in the Czech Republic. Deposits on the Isle of Skye, off the west coast of Scotland, were mined until 1960. In Colorado and in Clark County, Nevada, United States, there are deposits that are up to several hundred meters thick in places. Marine deposits have been worked in the Sisquoc Formation in Santa Barbara County, California near Lompoc and along the Southern California coast. This is the world's largest deposit of diatomite. Additional marine deposits have been worked in Maryland, Virginia, Algeria and the MoClay of Denmark. Freshwater lake deposits occur in Nevada, Oregon, Washington and California. Lake deposits also occur in interglacial lakes in the eastern United States, in Canada and in Europe in Germany, France, Denmark and the Czech Republic. The worldwide association of diatomite deposits and volcanic deposits suggests that the availability of silica from volcanic ash may be necessary for thick diatomite deposits. Diatomaceous earth is sometimes found on desert surfaces. Research has shown that the erosion of diatomaceous earth in such areas (such as the Bodélé Depression in the Sahara) is one of the most important sources of climate-affecting dust in the atmosphere.
Coghill made Andrew J. Moyer available to work on penicillin with Heatley, while Florey left to see if he could arrange for a pharmaceutical company to manufacture penicillin. As a first step to increasing yield, Moyer replaced sucrose in the growth media with lactose. An even larger increase occurred when Moyer added corn steep liquor, a byproduct of the corn industry that the NRRL routinely tried in the hope of finding more uses for it. The effect on penicillin was dramatic; Heatley and Moyer found that it increased the yield tenfold. At the Yale New Haven Hospital in March 1942, Anne Sheafe Miller, the wife of Yale University's athletics director, Ogden D. Miller, was succumbing to a streptococcal septicaemia contracted after a miscarriage. Her doctor, John Bumstead, was also treating John Fulton for an infection at the time. He knew that Fulton knew Florey, and that Florey's children were staying with him. He went to Fulton to plead for some penicillin. Florey had returned to the UK, but Heatley was still in the United States, working with Merck. A phone call to Richards released 5.5 grams of penicillin earmarked for a clinical trial, which was despatched from Washington, D. C., by air. The effect was dramatic; within 48 hours her 41 °C (106 °F) fever had abated and she was eating again. Her blood culture count had dropped from 100 to 150 bacteria colonies per millilitre to just one. Bumstead suggested reducing the penicillin dose from 200 milligrams; Heatley warned him not to.
== See also == Able Archer 83 – NATO military exercise that happened over a month after the Petrov incident Dead Hand – Soviet nuclear weapons-control system List of nuclear close calls Norwegian rocket incident – a rocket carrying scientific equipment to study the aurora borealis that resembled a submarine-launched Trident missile Vasily Arkhipov – the subject of another nuclear war-averting incident during the Cuban Missile Crisis World War III – situations resulting in close encounters of a third world war
Gonadotropin receptors are embedded in the surface of the target cell membranes and coupled to the G-protein system. Signals triggered by binding to the receptor are relayed within the cells by the cyclic AMP second messenger system. Gonadotropins are released under the control of gonadotropin-releasing hormone (GnRH) from the arcuate nucleus and preoptic area of the hypothalamus. The gonads — testes and ovaries — are the primary target organs for LH and FSH. The gonadotropins affect multiple cell types and elicit multiple responses from the target organs. As a simplified generalization, LH stimulates the Leydig cells of the testes and the theca cells of the ovaries to produce testosterone (and indirectly estradiol), whereas FSH stimulates the spermatogenic tissue of the testes and the granulosa cells of ovarian follicles, as well as stimulating production of estrogen by the ovaries. Although gonadotropins are secreted in a pulsatile manner (as a result of pulsatile GnRH release), unlike the case of GnRH and GnRH agonists, constant/non-pulsatile activation of the gonadotropin receptors by the gonadotropins does not produce functional inhibition. This can be seen during the first 7–10 weeks of pregnancy, where constantly high and progressively-increasing levels of hCG circulate and mediate production of estrogen and progesterone by the corpus luteum until the placenta takes over the production of these hormones.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.